Form 4: Caribou Biosciences Director Andrew Guggenhime Acquires Options
SEC Form 4 Filing
Director Andrew Guggenhime acquired options to purchase 40,500 shares of Caribou Biosciences common stock on February 20, 2025.
Summary
- On February 20, 2025, Andrew Guggenhime, a director of Caribou Biosciences, Inc., acquired options to purchase 40,500 shares of the company's common stock.
- The exercise price of the options is $1.41 per share.
- The options vest in monthly installments over a year, becoming fully vested on February 20, 2026, contingent upon continued service to the company.
- The options expire on February 19, 2035.
- Following the transaction, Guggenhime directly owns options for 40,500 shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing regarding stock options, so the sentiment is neutral.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedule of the options.
Industry Context
This filing is a routine disclosure related to insider transactions and provides transparency regarding the holdings of company directors. It's a standard practice for publicly traded companies.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director compensation and alignment of interests.
Key Dates
| Date | Description |
|---|---|
| 02/20/2025 | Date of transaction: Andrew Guggenhime acquired options to purchase common stock. |
| 02/20/2026 | Options fully vest, contingent upon continued service. |
| 02/19/2035 | Expiration date of the options. |
| 02/21/2025 | Date of signature on the Form 4 filing. |
Keywords
Caribou Biosciences, CRBU, Andrew Guggenhime, Director, Options, Beneficial Ownership, Form 4, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.